Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

25.0%

1 terminated/withdrawn out of 4 trials

Success Rate

75.0%

-11.5% vs industry average

Late-Stage Pipeline

75%

3 trials in Phase 3/4

Results Transparency

100%

3 of 3 completed trials have results

Key Signals

3 with results

Enrollment Performance

Analytics

Phase 3
3(75.0%)
Phase 1
1(25.0%)
4Total
Phase 3(3)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT03710291Phase 3Terminated

Evaluation of Effect of TRC101 on Progression of Chronic Kidney Disease in Subjects With Metabolic Acidosis

Role: lead

NCT03390842Phase 3Completed

Long-term Safety Extension to Study TRCA-301

Role: lead

NCT03317444Phase 3Completed

Evaluation of TRC101 in Subjects With Metabolic Acidosis Associated With Chronic Kidney Disease

Role: lead

NCT02809183Phase 1Completed

Evaluation of TRC101 in Subjects With Chronic Kidney Disease and Metabolic Acidosis

Role: lead

All 4 trials loaded